Related Experiment Video
Updated: Apr 3, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Terry-Elinor Reid, Joseph M Fortunak, Anthony Wutoh
1Molecular Modeling and Drug Discovery Core Laboratory for District of Columbia Center for AIDS Research (DC CFAR), Department of Pharmaceutical Sciences, Howard University, Washington, District of Columbia 20059, USA. x.simon.wang@gmail.com.
Abstract:
Receptor Tyrosine Kinases (RTKs) are essential components for regulating cell-cell signaling and communication events in cell growth, proliferation, differentiation, survival and metabolism. Deregulation of RTKs and their associated signaling pathways can lead to a wide variety of human diseases such as immunodeficiency, diabetes, arterosclerosis, psoriasis and cancer. Thus RTKs have become one of the most important drug targets families in recent decade. Pharmaceutical companies have dedicated their research efforts towards the discovery of small-molecule inhibitors of RTKs, many of which had been approved by the U.S. Food and Drug Administration (US FDA) or are currently in clinical trials. The great successes in the development of small-molecule inhibitors of RTKs are largely attributed to the use of modern cheminformatic approaches to identifying lead scaffolds. Those include the quantitative structure-activity relationship (QSAR) modeling, as well as the structure-, and ligand-based pharmacophore modeling techniques in this case. Herein we inspected the literature thoroughly in an effort to conduct a comparative analysis of major findings regarding the essential structure-activity relationships (SARs)/pharmacophore features of known active RTK inhibitors, most of which were collected from cheminformatic modeling approaches.
Insights
Receptor Tyrosine Kinases (RTKs) are crucial for cell signaling and are key drug targets for diseases like cancer. Cheminformatics, including QSAR and pharmacophore modeling, aids in discovering effective RTK inhibitors.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Computational Biology
Background:
- Receptor Tyrosine Kinases (RTKs) regulate vital cellular processes.
- RTK dysregulation is implicated in numerous diseases, including cancer, diabetes, and immunodeficiency.
- RTKs are a major focus for drug development due to their disease relevance.
Purpose of the Study:
- To conduct a comparative analysis of structure-activity relationships (SARs) and pharmacophore features of RTK inhibitors.
- To highlight the role of cheminformatic approaches in identifying effective RTK inhibitor scaffolds.
- To consolidate key findings from literature regarding RTK inhibitor design.
Main Methods:
- Literature review and comparative analysis.
- Examination of quantitative structure-activity relationship (QSAR) modeling findings.
- Analysis of structure-based and ligand-based pharmacophore modeling studies.
Main Results:
- Identified essential SARs and pharmacophore features for active RTK inhibitors.
- Demonstrated the utility of cheminformatics in lead scaffold identification for RTK inhibitors.
- Compiled critical information on successful RTK inhibitor discovery strategies.
Conclusions:
- Cheminformatic approaches are pivotal for the successful development of small-molecule RTK inhibitors.
- Understanding SARs and pharmacophore models accelerates the discovery of targeted therapies.
- This analysis provides a foundation for future RTK inhibitor research and drug design.
Related Concept Videos
01:26Drug Discovery: Overview
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Receptor Tyrosine Kinases
02:04Protein-protein Interfaces
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...